|  |  |  |
| --- | --- | --- |
| **Week** | **Content** | **Speaker** |
| 2025.2.19 | The Full Lifecycle of Drug Discovery & Development | Qingfeng He |
| 2025.2.26 | Nonclinical Results Analysis and Considerations: Part I | Qingfeng He |
| 2025.3.5 | Nonclinical Results Analysis and Considerations: Part II | Qingfeng He |
| 2025.3.12 | Introduction to Clinical Drug Metabolism Kinetics | Qingfeng He |
| 2025.3.19 | Introduction to Clinical Drug Effect Kinetics | Qingfeng He |
| 2025.3.26 | Introduction of Clinical Study | Qingfeng He |
| 2025.4.2 | Clinical Pharmacology Considerations for Drugs Used in Cancers: Taking Trastuzumab Deruxtecan as an Example Part I (A milestone for Breast Cancer Therapy) | Qingfeng He |
| 2025.4.9 | Clinical Pharmacology Considerations for Drugs Used in Cancers: Taking Trastuzumab Deruxtecan as an Example Part II (A milestone for Breast Cancer Therapy) | Qingfeng He |
| 2025.4.16 | Clinical Pharmacology Considerations for Drugs Used in Cancers: Taking Sotorasib as an Example (Undruggable to Druggable to Rejection) | Qingfeng He |
| 2025.4.23 | Clinical Pharmacology Considerations for Drugs Used in Nervous System Diseases (Part 2): Taking Asenapine as an Example | Qingfeng He |
| 2025.4.30 | Clinical Pharmacology Considerations for Drugs Used in Endocrine System Diseases (Part 1): Taking GLP-1 Receptor Agonists as an Example | Qingfeng He |
| 2025.5.7 | Clinical Pharmacology Considerations for Drugs Used in Endocrine System Diseases (Part 2): Taking SGLT-2 Receptor Inhibitors as an Example | Qingfeng He |
| 2025.5.14 | Clinical Pharmacology Considerations for Drugs Used in Respiratory System Diseases: Taking Nirmatrevir/Ritonavir as an Example | Qingfeng He |
| 2025.5.21 | Clinical Pharmacology Considerations for Drugs Used in Immune System Diseases: Taking Belimumab as an Example | Qingfeng He |
| 2025.28 | Clinical Pharmacology Considerations for Cancer Therapeutic Drugs (Part 1): Taking Pembrolizumab as an Example | Qingfeng He |
| 2025.6.4 | Clinical Pharmacology Considerations for Cancer Therapeutic Drugs (Part 2): Taking Zanubrutinib as an Example | Qingfeng He |
| 2025.6.11 | Presentation | Qingfeng He |
| 2025.6.18 | Presentation | Qingfeng He |